Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms

Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity. In an attempt to improve response and avoid the adverse effects of this drug, we evaluated the co...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortés, Alicia Arenas, Diaz, Rosa Ayala, Hernández-Campo, Pilar, Gorrochategui, Julián, Primo, Daniel, Robles, Alicia, Morales, María Luz, Ballesteros, Joan, Rapado, Inmaculada, Gallardo, Miguel, Linares, María, Martínez-López, Joaquín
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518898/
https://www.ncbi.nlm.nih.gov/pubmed/30545926
http://dx.doi.org/10.3324/haematol.2018.201038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6518898/
https://www.ncbi.nlm.nih.gov/pubmed/30545926
http://dx.doi.org/10.3324/haematol.2018.201038

Ejemplares similares